CD274 and hepatocellular carcinoma: This suggests that the precise treatment of DDR pathway involves a considerable number of HCC patients, and the targeted therapy of PARP inhibitors and the immunotherapy of PD-1/PD-L1 have a broad prospect in the study of HCC patients.